Cancers (Mar 2023)

Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways and <i>COP1</i> in Metastasis

  • Jerry Xiao,
  • Utsav Sharma,
  • Abolfazl Arab,
  • Sohit Miglani,
  • Sonakshi Bhalla,
  • Shravanthy Suguru,
  • Robert Suter,
  • Reetu Mukherji,
  • Marc E. Lippman,
  • Paula R. Pohlmann,
  • Jay C. Zeck,
  • John L. Marshall,
  • Benjamin A. Weinberg,
  • Aiwu Ruth He,
  • Marcus S. Noel,
  • Richard Schlegel,
  • Hani Goodarzi,
  • Seema Agarwal

DOI
https://doi.org/10.3390/cancers15061831
Journal volume & issue
Vol. 15, no. 6
p. 1831

Abstract

Read online

Circulating tumor cells (CTCs), a population of cancer cells that represent the seeds of metastatic nodules, are a promising model system for studying metastasis. However, the expansion of patient-derived CTCs ex vivo is challenging and dependent on the collection of high numbers of CTCs, which are ultra-rare. Here we report the development of a combined CTC and cultured CTC-derived xenograft (CDX) platform for expanding and studying patient-derived CTCs from metastatic colon, lung, and pancreatic cancers. The propagated CTCs yielded a highly aggressive population of cells that could be used to routinely and robustly establish primary tumors and metastatic lesions in CDXs. Differential gene analysis of the resultant CTC models emphasized a role for NF-κB, EMT, and TGFβ signaling as pan-cancer signaling pathways involved in metastasis. Furthermore, metastatic CTCs were identified through a prospective five-gene signature (BCAR1, COL1A1, IGSF3, RRAD, and TFPI2). Whole-exome sequencing of CDX models and metastases further identified mutations in constitutive photomorphogenesis protein 1 (COP1) as a potential driver of metastasis. These findings illustrate the utility of the combined patient-derived CTC model and provide a glimpse of the promise of CTCs in identifying drivers of cancer metastasis.

Keywords